Steven G DuBois

Trials

Studies that name Steven G DuBois as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:09 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT03936465 · Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

  Dana-Farber Cancer Institute · completed · Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric · principal investigator
• Ph3
  NCT03126916 · Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  Children's Oncology Group · recruiting · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma · principal investigator
• Ph3
  NCT02306161 · Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  National Cancer Institute (NCI) · active not recruiting · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
  R01CA214912 · NCI · DANA-FARBER CANCER INST · fiscal years 2018 to 2023 · $347,922 awarded in 2023
  Same name and institution; not confirmed by an ID
• Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
  R01CA172067 · NCI · DANA-FARBER CANCER INST · fiscal years 2013 to 2017 · $363,425 awarded in 2017
  Same name and institution; not confirmed by an ID
• PhI trial of dual PI3K/BRD4 inhibitor SF1126 in neuroblastoma IND124993 (12/2/14)
  R01FD005740 · FDA · DANA-FARBER CANCER INST · fiscal years 2017 · $250,000 awarded in 2017
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• COG NCTN Network Group Operations Center
  U10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026
  Named on NCT03126916, NCT02306161
• Children's Oncology Group Chair's Grant
  U10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013
  Named on NCT02306161